Article Versions Notes

Cross RW, Wiethoff CM, Brown-Augsburger P, Berens S, Blackbourne J, Liu L, Wu X, Tetreault J, Dodd C, Sina R, et al. The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms. Pathogens. 2023; 12(12):1408. https://doi.org/10.3390/pathogens12121408

Cross, Robert W., Christopher M. Wiethoff, Patricia Brown-Augsburger, Shawn Berens, Jamie Blackbourne, Ling Liu, Xiaohua Wu, Jonathan Tetreault, Carter Dodd, Ramtin Sina, and et al. 2023. "The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms" Pathogens 12, no. 12: 1408. https://doi.org/10.3390/pathogens12121408

Cross, R. W., Wiethoff, C. M., Brown-Augsburger, P., Berens, S., Blackbourne, J., Liu, L., Wu, X., Tetreault, J., Dodd, C., Sina, R., Witcher, D. R., Newcomb, D., Frost, D., Wilcox, A., Borisevich, V., Agans, K. N., Woolsey, C., Prasad, A. N., Deer, D. J., ... Geisbert, T. W. (2023). The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms. Pathogens, 12(12), 1408. https://doi.org/10.3390/pathogens12121408